Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2005

Conditions

HIV Infections

Interventions

BIOLOGICAL

EP HIV-1090

Trial Locations (5)

Saint Louis Univ. School of Medicine, HVTU, St Louis

Brigham and Women's Hosp. CRS, Boston

Fenway Community Health Clinical Research Site (FCHCRS), Boston

Miriam Hospital's HVTU, Providence

Gaborone Prevention/Treatment Trials CRS, Gaborone

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00054860 - Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter